Accueil>>Signaling Pathways>> Neuroscience>> Histamine Receptor>>Fexofenadine HCl

Fexofenadine HCl (Synonyms: MDL 16455A)

Catalog No.GC10966

Le chlorhydrate de fexofénadine (MDL-16455) est un antagoniste des récepteurs H1 actif par voie orale et non sédatif.

Products are for research use only. Not for human use. We do not sell to patients.

Fexofenadine HCl Chemical Structure

Cas No.: 153439-40-8

Taille Prix Stock Qté
10mM (in 1mL DMSO)
34,00 $US
En stock
10mg
35,00 $US
En stock
50mg
90,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Fexofenadine hydrochloride (MDL-16455 hydrochloride), a H1R antagonist, is an anti-allergic agent used in seasonal allergic rhinitis and chronic idiopathic urticarial (person aged ≥16 years)[1].

Fexofenadine hydrochloride (MDL-16455 hydrochloride) (100 µM; 1 hour) effectively blocks phosphorylated p38 activation in histamine-induced nasal fibroblasts[2].

Fexofenadine hydrochloride (MDL-16455 hydrochloride) (5-20 mg/kg; oral daily for 3 weeks) dose-dependently suppresses eosinophilia in C57BL/6 mice infected with T. spiralis[1].

References:
[1]. Watanabe N, et al. The effects of fexofenadine on eosinophilia and systemic anaphylaxis in mice infected with Trichinella spiralis. Int Immunopharmacol. 2004 Mar;4(3):367-75.
[2]. Park IH, et al. Histamine Promotes the Release of Interleukin-6 via the H1R/p38 and NF-κB Pathways in NasalFibroblasts. Allergy Asthma Immunol Res. 2014 Nov;6(6):567-72.

Avis

Review for Fexofenadine HCl

Average Rating: 5 ★★★★★ (Based on Reviews and 17 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Fexofenadine HCl

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.